Evidence map›Paper›PMID 25538269›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2015

Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy.

Shilpa Sharma, Carlo Brugnara, Rebecca A Betensky, Sushrut S Waikar

Open access · bronzeAbstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Transfusion strategies for neonates: current perspectives.Annals of medicine and surgery (2012) · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Intensive Care Unit-Acquired Weakness in Patients With Acute Kidney Injury: A Contemporary Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Review
  14. Article
  15. Phosphate Dysregulation and Neurocognitive Sequelae.Advances in experimental medicine and biology · 2022
    Article
  16. Article
  17. Review
  18. Staying on target with continuous dialysis.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shilpa SharmaRenal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; ssharma6@partners.org.
Carlo BrugnaraDepartment of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; and.
Rebecca A BetenskyDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.
Sushrut S WaikarRenal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;
Brigham and Women's Hospital · USHarvard University · US

Funding

Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007527 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1986 to 2021
$8.8M
Biomarkers of Kidney PathologyR01DK093574 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI WAIKAR, SUSHRUT S. · 2012 to 2015
$2.4M
NCATS NIH HHS 8UL1-TR000170-05NCATS NIH HHS UL1 TR000170NIDDK NIH HHS R01 DK093574NIDDK NIH HHS T32 DK007527NIDDK NIH HHS T32-DK007527
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHypophosphatemia is a frequent complication during continuous renal replacement therapy (CRRT), a dialytic technique used to treat AKI in critically ill patients. This study sought to confirm that phosphate depletion during CRRT may decrease red blood cell (RBC) concentration of 2,3-diphosphoglycerate (2,3-DPG), a crucial allosteric effector of hemoglobin's (Hgb's) affinity for oxygen, thereby leading to impaired oxygen delivery to peripheral tissues. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Phosphate mass balance studies were performed in 20 patients with severe AKI through collection of CRRT effluent. RBC concentrations of 2,3-DPG, venous blood gas pH, and oxygen partial pressure required for 50% hemoglobin saturation (P50) were measured at CRRT initiation and days 2, 4, and 7. Similar measurements were obtained on days 0 and 2 in a reference group of 10 postsurgical patients, most of whom did not have AKI. Associations of 2,3-DPG with laboratory parameters and clinical outcomes were examined using mixed-effects and Cox regression models.

resultsMean 2,3-DPG levels decreased from a mean (±SD) of 13.4±3.4 µmol/g Hgb to 11.0±3.1 µmol/g Hgb after 2 days of CRRT (P<0.001). Mean hemoglobin saturation P50 levels decreased from 29.7±4.4 mmHg to 26.7±4.0 mmHg (P<0.001). No significant change was seen in the reference group. 2,3-DPG levels after 2 days of CRRT were not significantly lower than those in the reference group on day 2. Among patients receiving CRRT, 2,3-DPG decreased by 0.53 µmol/g Hgb per 1 g phosphate removed (95% confidence interval 0.38 to 0.68 µmol/g Hgb; P<0.001). Greater reductions in 2,3-DPG were associated with higher risk for death (hazard ratio, 1.43; 95% confidence interval, 1.09 to 1.88; P=0.01).

conclusionsCRRT-induced phosphate depletion is associated with measurable reductions in RBC 2,3-DPG concentration and a shift in the O2:Hgb affinity curve even in the absence of overt hypophosphatemia. 2,3-DPG reductions may be associated with higher risk for in-hospital death and represent a potentially avoidable complication of CRRT.

Indexed as

2,3-DiphosphoglycerateAcute Kidney InjuryAgedAged, 80 and overBiomarkersCase-Control StudiesDown-RegulationErythrocytesFemaleHumansHydrogen-Ion ConcentrationHypophosphatemiaMaleMiddle AgedOxygenOxyhemoglobins2,3-DiphosphoglycerateBiomarkersOxygenOxyhemoglobinsacute renal failuredialysismortality

Identifiers

PMID25538269
PMCPMC4284404
OpenAlexW2106569503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.